Tag Archives: Jay Olson

Axovant Gene Therapies (AXGT) Gets a Hold Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Hold rating on Axovant Gene Therapies (AXGT – Research Report) today. The company’s shares closed yesterday at $1.31, close to its 52-week low of $0.93. Olson observed: “AXGT hosted an R&D day featuring valuable

Amgen Inc (AMGN): New Buy Recommendation for This Healthcare Giant

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Amgen Inc (AMGN – Research Report), with a price target of $224. The company’s shares closed yesterday at $192.43. Olson said: “Preclinical data on AMGN’s small

Spero Therapeutics Inc (SPRO) Receives a Buy from Oppenheimer

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Spero Therapeutics Inc (SPRO – Research Report). The company’s shares closed on Friday at $13.18. According to TipRanks.com, Olson is ranked 0 out of 5 stars

Enanta Pharmaceuticals (ENTA) Receives a Hold from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The company’s shares closed yesterday at $99.66. According to TipRanks.com, Olson has 0 stars on 0-5 star ranking scale with an average return of

Intec Pharma Ltd (NTEC) Gets a Buy Rating from Oppenheimer

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Intec Pharma Ltd (NTEC – Research Report). The company’s shares opened today at $6.76. According to TipRanks.com, Olson is a 1-star analyst with an average return

Neurocrine (NBIX) Received its Third Buy in a Row

After Barclays and Cantor Fitzgerald gave Neurocrine (NASDAQ: NBIX) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Jay Olson maintained a Buy rating on Neurocrine yesterday and set a price target of $110.